David Ermert

David Ermert has a diverse and extensive work experience in the field of microbiology and infectious diseases. David has held various roles at different research institutions.

From 2006 to 2010, Ermert worked as a Researcher PhD Student at the Max Planck Institute for Infection Biology. During this time, they focused on studying neutrophil extracellular traps (NETs) as a defense mechanism against microbes. David made significant contributions to the understanding of NETs' protein composition, anti-fungal properties, and their link to reactive oxygen species (ROS) and neutrophil cell death.

In 2010, Ermert joined Umeå University as a Postdoctoral Fellow, where their research focused on the biology of neutrophils and the host-pathogen interaction. David investigated the role of neutrophils in fungal infections and the involvement of neutrophil extracellular traps (NETs) in host defense.

In 2012, Ermert joined the University of Massachusetts Medical School as a Research Fellow. Here, they worked on the importance of complement in bacterial virulence, particularly on S. pyogenes. David contributed to the establishment of a transgenic mouse model expressing human complement factors and described a novel human fusion-protein effective against gram-negative and gram-positive bacteria.

Starting in 2014, Ermert worked at Lund University, initially as a Researcher (Postdoctoral Fellow) and later as a Senior Researcher and Associate Professor (Docent). Their research in complement biology focused on complement inhibitors, specifically C4b-binding protein (C4BP), and their involvement in various fields such as diabetes, cancer, autoimmune diseases, and infectious diseases, particularly in microbiology and infectious diseases.

Most recently, Ermert joined BioInvent International AB in 2018. David held the positions of Research Scientist and Senior Research Scientist, but specific contributions or roles during their tenure were not provided in the structured information.

David Ermert began their education in 2000 at the University of Tübingen, where they pursued a Master of Science degree in Biochemistry. David completed this program in 2006. In 2005, they also enrolled at The University of Göttingen to pursue a Master of Science degree in Protein Biochemistry, which they completed in 2006. Additionally, in 2003-2004, David attended Ludwig-Maximilians-Universität München, focusing on Organic Chemistry.

In terms of certifications, David obtained several from AALAS (American Association for Laboratory Animal Science). In January 2018, they completed the Transgenics Training Program. In June 2017, they completed the Animal Biosafety Training Program. In October 2011, David obtained permission for the use of rodents as experimental animals in A-BSL 1 and 2.